SEC Form 5 · accession 0001209191-17-010246
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John T Potts Jr.
Director
Period of report
Dec 31, 2016
Accepted (ET)
Feb 13, 2017 · 8:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326110
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 2, 2016 | M | 135,500 | $0.2161 | A | 235,500 | D | |
| Common Stock | Aug 3, 2016 | G | 100,000 | $0.00 | D | 135,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.2161 | Aug 2, 2016 | M | 135,500 | D | — | Mar 17, 2024 | Common Stock | 135,500 | 134,800 | D |
Explanation of responses
- F1Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is March 17, 2014.